Peak Group: Subsidiary Obtains Drug Registration Certificate for Injection Phosphatidylserine

The Peak Group announced that its wholly-owned subsidiary, Peak Pharmaceuticals, recently received the injection phosphoric acid special thiazole amine "Drug Registration Certificate" issued by the National Medical Products Administration, with a specification of 200mg, and the approval number valid until July 20, 2031. As of the date of the announcement, the research and development investment in this drug project is approximately 12.5192 million yuan. Currently, 22 companies have been approved for registration and listing of this drug. This certification marks Peak Pharmaceuticals' qualification for production and sales, which is beneficial for product line enrichment, but production and sales are subject to multiple factors and uncertainties.